EUCTR2013-002713-35-GR进行中（未招募）不适用
Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms
MediPsych SA0 个研究点目标入组 100 人开始时间: 2014年4月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient must meet all the following criteria to be eligible for this study:
- •1. The patients will be male or female, aged from 18 to 65 years old.
- •2. The patient is willing and able to provide signed informed consent form. For patients in acute relapse, legal representatives will be required to sign the consent form.
- •3. The patient will have an official diagnosis of Schizophrenia or Schizoaffective disorder according to the DSM-IV TR criteria and will display the cognitive and negative symptoms of schizophrenia.
- •4. The patient will be either at relapse of the disorder (Group 1) or at the early stages of the disease and/or stabilised (Group 2) and takes standard antipsychotic medication.
- •5. If the patient is sexually active, then s/he must satisfy one of the following criteria:
- •a) For Women: They should not be pregnant or be in lactation period. They should be either surgically sterilized or be in postmenopausal period. The patient’ partner should apply an accepted and highly effective contraceptive regimen (a shape which leads to failure rate < 1%) for 4 weeks before the preliminary assessment.
- •b) For Men: They should be either surgically sterilized or patient or patient’partner should use an accepted and highly effective method of contraception during administration and for 4 weeks after the last dose of research product.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient who meets any of the following criteria will be excluded from this study.
- •1. The patient is hypersensitive to tolcapone.
- •2. The patient has hereditary problems of galactose intolerance, Lapp lactose deficiency or glucose - galactose malabsorption.
- •3. The patient suffers from severe physical and neurological active disease and /or present history of Neuroleptic Malignant Syndrome.
- •4. The patient is suffering from liver dysfunction and / or increased liver enzymes (serum alanine aminotransferase (ALT) and / or aspartamikis aminotransferase (AST) = 1,5 x ULN)
- •5. The patient suffers from severe renal impairment (creatinine clearance <30 ml / min)
- •6. The patient suffers from epilepsy
- •7. The patient is suffering from severe dyskinesia and/or from non - traumatic Rhabdomyolysis or Hyperthermia.
- •8. The patient is suffering from pheochromocytoma.
- •9. The patient has a previous history of Neuroleptic Malignant Syndrome (NMS).
- •10. The patient has suffered a myocardial infarction within the last 6 months.
- •11. The patient receives treatment with non - selective inhibitors of mono - amino - oxidase (MAO) inhibitors (eg phenelzine and tranylcypromine). If the patient is treated with a selective inhibitor of MAO –B, it should not exceed the recommended dose (eg for selegiline < 10mg/day) when co-administered with tolcapone .
- •12. The patient receives other enzyme inhibitor COMT drugs (e.g. entacapone, clozapine) or other dopaminergic drugs.
- •13. The patient is being treated with levodopa and benserazide.
- •14. The patient receives or has received in the past another investigational drug, biologic or device within 4 weeks of the preliminary assessment.
- •15. The patient receives antipsychotic medication known to exclude D1 receptors with high binding (affinity) such as flupenthixol , fluphenazine , ziprasidone , chlorpromazine , and olanzapine (Ki 4, 6, 30, 35 and 48 respectively).
- •16. The patient according to the investigator is unable to meet the requirements of the study.
- •17. The patient has a current or recent history of drug or alcohol or shows reluctance to decrease the consumption of alcohol.
研究者
相似试验
已完成
不适用
A randomized controlled trial of the effectiveness of simplified CPR education for the general public.Cardiac arrestJPRN-C000000321Kyoto University200
招募中
不适用
A randomized controlled trial of the effectiveness of a new cognitive behavioral intervention; anti-rumination training for depressed older peoplerumination10027946depressionNL-OMON29766Parnassia (Den Haag)128
招募中
Unknown
se of brain stimulation for treatment of DepressioCTRI/2023/03/050546All India Institute of Medical Sciences New Delhi
已完成
不适用
urse led brief intervention for reducing psychoactive substance use among elderlyCTRI/2021/03/032254Pt BDS PGIMS Rohtak60
已完成
不适用
A randomised controlled trial of the effectiveness of prism spectacles in reducing the disability of patients with age-related macular degeneration (ARMD)Eye DiseasesAge-related macular degenerationISRCTN00821605The Health Foundation (UK)225